Slimb Inhibitors
Chemical inhibitors of the Slimb protein function primarily by impeding the ubiquitin-proteasome pathway, a cellular mechanism responsible for the degradation of proteins. The ubiquitin-proteasome system plays a crucial role in maintaining cellular protein homeostasis by tagging defective or unneeded proteins with ubiquitin, signaling their transport to the proteasome for degradation. Slimb's role in this process involves the recognition and tagging of specific proteins with ubiquitin. By using proteasome inhibitors such as MG132, Lactacystin, Epoxomicin, Bortezomib, Carfilzomib, Ixazomib, Delanzomib, Marizomib, Oprozomib, Velcade, and MLN2238, the degradation process is halted. This results in the accumulation of proteins within the cell, including those that are normally targeted by Slimb. Consequently, the function of Slimb is indirectly inhibited, as the proteins it would typically mark for degradation remain undegraded and accumulate within the cell.
These inhibitors employ a variety of mechanisms to disrupt the ubiquitin-proteasome pathway. MG132, for instance, is a reversible inhibitor, while Lactacystin and Marizomib bind irreversibly to the proteasome, leading to sustained inhibition. Bortezomib and its equivalent, Velcade, along with Carfilzomib, form a class of inhibitors that specifically target the catalytic activity of the proteasome. Ixazomib and its bioactive form MLN2238 are characterized by their small molecular structure and ability to inhibit the proteasome, thereby affecting the function of Slimb. Delanzomib and Oprozomib further contribute to this pool of inhibitors with their unique binding properties and mechanisms of action. Although not directly targeting Slimb, these chemicals manage to inhibit its function by preventing the proteolytic turnover of proteins within the ubiquitin-proteasome pathway.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a potent proteasome inhibitor which can inhibit the degradation of ubiquitinated proteins. Since Slimb is part of the ubiquitin-proteasome pathway, inhibiting the proteasome can lead to a functional inhibition of Slimb by preventing the turnover of proteins that Slimb targets for degradation. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
Lactacystin is another proteasome inhibitor that irreversibly binds to the catalytic subunit of the proteasome. By inhibiting the proteasome, Lactacystin causes an accumulation of proteins that are normally degraded, indirectly inhibiting the function of Slimb by halting the degradation process it mediates. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $134.00 $215.00 $440.00 $496.00 | 19 | |
Epoxomicin is a selective proteasome inhibitor that covalently binds to and inhibits the chymotrypsin-like activity of the proteasome. This inhibition leads to an accumulation of ubiquitinated proteins, which can indirectly inhibit the function of Slimb by affecting the pathway it regulates. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a dipeptidyl boronic acid that acts as a proteasome inhibitor and is known to block the degradation of ubiquitinated proteins. This blockage can hinder the function of Slimb by preventing the proteolytic processing of its target proteins within the ubiquitin-proteasome pathway. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $40.00 | ||
Carfilzomib is a tetrapeptide epoxyketone and a selective proteasome inhibitor. By inhibiting the proteasome, Carfilzomib can cause an accumulation of proteins targeted for degradation by Slimb, leading to functional inhibition of the Slimb pathway. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Ixazomib is a small molecule proteasome inhibitor. Through proteasome inhibition, Ixazomib can indirectly inhibit Slimb function by preventing the degradation of proteins that Slimb tags for ubiquitination and subsequent degradation. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
Delanzomib is another proteasome inhibitor that binds and inhibits the chymotrypsin-like activity of the proteasome. By inhibiting this function, Delanzomib can indirectly inhibit the function of Slimb by disrupting the proteolytic turnover of its substrates. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib is an orally bioavailable proteasome inhibitor. Its mechanism of inhibiting the proteasome can result in functional inhibition of Slimb by increasing the levels of proteins that are normally marked for degradation by the ubiquitin-proteasome system. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Pyrazolanthrone, also known as SP600125, is an inhibitor of JNK which is involved in a range of cellular processes. Inhibition of JNK can lead to the functional inhibition of Slimb by altering the signaling pathways that Slimb is involved in, specifically those that regulate protein degradation. | ||||||